XML 47 R32.htm IDEA: XBRL DOCUMENT v3.25.2
Identifiable Intangible Assets, Net and Goodwill (Tables)
 6 Months Ended
Jun. 29, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
June 29, 2025December 31, 2024
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$100,537 $(67,907)$32,629 $99,397 $(65,044)$34,353 
Brands
1,274 (1,012)262 1,277 (992)285 
Licensing agreements and other2,740 (1,603)1,137 2,724 (1,513)1,210 
104,551 (70,522)34,028 103,397 (67,549)35,848 
Indefinite-lived intangible assets
IPR&D(a)
18,213 18,213 18,893 18,893 
Licensing agreements and other(b)
461 461 670 670 
18,674 18,674 19,563 19,563 
Identifiable intangible assets(c)
$123,224 $(70,522)$52,702 $122,961 $(67,549)$55,411 
(a)The changes in the gross carrying amounts primarily reflect the transfer of $590 million from IPR&D to developed technology rights for talazoparib (Talzenna), as well as the impact of foreign exchange.
(b)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
(c)The decrease is primarily due to amortization expense of $2.4 billion.
Schedule of Indefinite Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
June 29, 2025December 31, 2024
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$100,537 $(67,907)$32,629 $99,397 $(65,044)$34,353 
Brands
1,274 (1,012)262 1,277 (992)285 
Licensing agreements and other2,740 (1,603)1,137 2,724 (1,513)1,210 
104,551 (70,522)34,028 103,397 (67,549)35,848 
Indefinite-lived intangible assets
IPR&D(a)
18,213 18,213 18,893 18,893 
Licensing agreements and other(b)
461 461 670 670 
18,674 18,674 19,563 19,563 
Identifiable intangible assets(c)
$123,224 $(70,522)$52,702 $122,961 $(67,549)$55,411 
(a)The changes in the gross carrying amounts primarily reflect the transfer of $590 million from IPR&D to developed technology rights for talazoparib (Talzenna), as well as the impact of foreign exchange.
(b)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
(c)The decrease is primarily due to amortization expense of $2.4 billion.